27 Following that, several anti-angiogenic drugs targeting VEGF or blocking the activity of its receptor, have been approved, and are commonly used in the treatment of different cancers. 28-29 In 2011, however, the FDA rescinded its approval due to contradictory results from previous studies and reports of resultant elevated toxicity. 31,32. This evidence concerns the gene VEGFA and cancer.